Ahammune Biosciences is an innovation-led DSIR recogized drug discovery company focused on developing new treatment options for immune mediated diseases of skin, with current focus on the depigmenting disorder, Vitiligo. There is an enormous unmet global need in treating patients with vitiligo. The mission of Ahammune Biosciences is to arrest the progress of Vitiligo and to induce repigmentation of depigmented patches. We have identified a new druggable pathway to be involved in Vitiligo pathogenesis and are developing new chemical/molecular entities (NCE/NME’s) targeting this pathway.